Hwang Lih-Hwa
Hepatitis Research Center, National Taiwan University Hospital and Graduate Institute of Microbiology, National Taiwan University College of Medicine, 7 Chung-Shan S. Road, Taipei 10016, Taiwan, R.O.C.
J Biomed Sci. 2006 Jul;13(4):453-68. doi: 10.1007/s11373-006-9085-7. Epub 2006 Apr 22.
Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide. Effective therapy to this cancer is currently lacking, creating an urgent need for new therapeutic strategies for HCC. Gene therapy approach that relies on the transduction of cells with genetic materials, such as apoptotic genes, suicide genes, genes coding for antiangiogenic factors or immunomodulatory molecules, small interfering RNA (siRNA), or oncolytic viral vectors, may provide a promising strategy. The aforementioned strategies have been largely evaluated in the animal models with HCC or liver metastasis. Due to the diversity of vectors and therapeutic genes, being used alone or in combination, gene therapy approach may generate great beneficial effects to control the growth of tumors within the liver.
肝细胞癌（HCC）是全球最常见的癌症之一。目前缺乏针对这种癌症的有效治疗方法，因此迫切需要针对HCC的新治疗策略。基因治疗方法依赖于用遗传物质转导细胞，如凋亡基因、自杀基因、编码抗血管生成因子或免疫调节分子的基因、小干扰RNA（siRNA）或溶瘤病毒载体，可能提供一种有前景的策略。上述策略已在HCC或肝转移的动物模型中进行了大量评估。由于单独或联合使用的载体和治疗基因的多样性，基因治疗方法可能对控制肝脏内肿瘤的生长产生巨大的有益效果。
